: Kor. J. Fertil. Steril., Vol. 31, No. 2, 2004, 6 GnRH-agonist PBR 1, 2, Apoptosis and Peripheral Benzodiazepin Receptor

Similar documents
歯 PDF

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

γ

untitled

5

01 Buffers & Gel Stain Buffers 3 Gel Stain SilverStar Staining Kit 6

KISEP Otology Korean J Otolaryngol 2000;43: 마우스대식세포주에서항산화제및 Dexamethasone 이유발형산화질소합성효소발현과산화질소생성에미치는효과 강준명 여상원 이흥엽 장기홍 서병도 Effect of Antioxidants

431_439특집_문신용


Kaes010.hwp

Can032.hwp

012임수진

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

09-감마선(dh)

Lumbar spine


44-4대지.07이영희532~

( )Jkstro011.hwp

목 차 회사현황 1. 회사개요 2. 회사연혁 3. 회사업무영역/업무현황 4. 등록면허보유현황 5. 상훈현황 6. 기술자보유현황 7. 시스템보유현황 주요기술자별 약력 1. 대표이사 2. 임원짂 조직 및 용도별 수행실적 1. 조직 2. 용도별 수행실적

Statistical Data of Dementia.

°ø±â¾Ð±â±â

< D B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A E687770>

hwp

untitled

DBPIA-NURIMEDIA

항체 포털 서비스 Preparation Peptide 총 4주 소요 / 473,000 ~ 511,000 Free of charge 2~3 days 243,000 ~ 281,000 의뢰서 작성 Peptide epitope prediction 유전자 정보

전체 목차 1. 주류 일반 2. 기능성 3. 숙취 4. 주세법 5. 주류 일반 상식 6. 우리술 즐기기

김범수

Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

KJOG Vol. 55, No. 12, 2012 내막증이 있는 경우. 골반유착으로 인한 해부학적 변화가 발생할 수 있 으며 이로 인해 난자의 배출 장애가 발생할 수 있다. 또한 복막액내의 interleukin-1, prostaglandin, macrophage, pro

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re

-, BSF BSF. - BSF BSF ( ),,. BSF -,,,. - BSF, BSF -, rrna, BSF.

54 한국교육문제연구제 27 권 2 호, I. 1.,,,,,,, (, 1998). 14.2% 16.2% (, ), OECD (, ) % (, )., 2, 3. 3

A 617

Journal of Educational Innovation Research 2019, Vol. 29, No. 2, pp DOI: 3 * Effects of 9th

大学4年生の正社員内定要因に関する実証分析

Seok Joo Kim, et al. Hepatocellular Carcinoma with Severe Hypoglycemia : Involvement of Insulin- like Growth Fa ctor I & II a nd Insulin- like Growth


제 출 문 경상북도 경산시 농업기술센터 귀하 본 보고서를 6차산업수익모델시범사업 농산물가공품개발 연구용역 과제의 최종보고서로 제출합니다 년 11 월 19 일 주관연구기관명 : 영남대학교 총괄연구책임자 : 한 기 동 연 구 원 : 김 상 욱 이 수 형 이 상

139~144 ¿À°ø¾àħ

한국성인에서초기황반변성질환과 연관된위험요인연구


(Establishment and Management of Proteomics Core Facility)

388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR

歯1.PDF

농림수산식품부장관귀하 이보고서를 팥의대사성질환개선및기능성규명 에관한연구의최종보고서로제출 합니다 년 2 월 11 일 - 1 -

충북의대학술지 Chungbuk Med. J. Vol. 27. No. 1. 1~ Charcot-Marie-Tooth Disease 환자의마취 : 증례보고 신일동 1, 이진희 1, 박상희 1,2 * 책임저자 : 박상희, 충북청주시서원구충대로 1 번지, 충북대학교

THE JOURNAL OF KOREAN INSTITUTE OF ELECTROMAGNETIC ENGINEERING AND SCIENCE Sep.; 30(9),


Treatment and Role of Hormaonal Replaement Therapy

077~088 해계 유침과 전침이

Jkbcs032.hwp

Pierce-Plus-Alpha.pdf

No Slide Title


Subject : 귀사의 일익번창하심을 진심으로 기원합니다.


2003_KR piv

09구자용(489~500)

acdc EQ 충전기.hwp

MPAL-VI-Pneu_BES_V_ a_ k1


590호(01-11)

00약제부봄호c03逞풚

1..

서론 34 2

Journal of Educational Innovation Research 2018, Vol. 28, No. 4, pp DOI: * A Research Trend

Journal of Educational Innovation Research 2016, Vol. 26, No. 3, pp DOI: * The Grounds and Cons

untitled

<32382DC3BBB0A2C0E5BED6C0DA2E687770>

02¿ÀÇö¹Ì(5~493s

10(3)-10.fm

Microsoft Word - 3-차수경.DOC

( )Kju269.hwp

10-1(조사보고서).PDF

untitled

DBPIA-NURIMEDIA

歯5-2-13(전미희외).PDF

,......

2000 년도산학협동연구비 Korean Circulation J 2002;32 12 : 생쥐의 Adriamycin 유발심근증모델에서 IGF-1 의 심근보호효과 박철수 윤호중 조은주 오용석 백상홍 이정화강진형 정욱성 채장성 김재형 최규보 홍순조 Cardi

Journal of Educational Innovation Research 2018, Vol. 28, No. 4, pp DOI: 3 * The Effect of H

중 국 6 대 패 션 시 장 조 사 보 고 서 < 2004 년 상 해 10 대 매 장 10대 패 션 제 품 의 브 랜 드 시 장 점 유 뮬 > 제 품 브 랜 드 시 장 점 유 율 제 품 브 랜 드 시 장 점유 율 C O N C H P LA Y B O Y

untitled

Jkbcs016(92-97).hwp


한국 출산력의 저하 요인에 관한 연구

09È«¼®¿µ 5~152s

7.ƯÁýb71ÎÀ¯È« š

Journal of Educational Innovation Research 2018, Vol. 28, No. 3, pp DOI: The Effect of Caree


Microsoft Word - 2-이우석.DOC

Aging Tissue Bank κ κ κ κ (9 월호에계속...) 2

03이경미(237~248)ok

Kinematic analysis of success strategy of YANG Hak Seon technique Joo-Ho Song 1, Jong-Hoon Park 2, & Jin-Sun Kim 3 * 1 Korea Institute of Sport Scienc

27 2, * ** 3, 3,. B ,.,,,. 3,.,,,,..,. :,, : 2009/09/03 : 2009/09/21 : 2009/09/30 * ICAD (Institute for Children Ability

CERIUM OXIDE Code CeO CeO 2-035A CeO 2-035B CeO REO % CeO 2 /REO % La 2 O 3 /REO %

Journal of Educational Innovation Research 2018, Vol. 28, No. 3, pp DOI: * Strenghening the Cap

12이문규

Crt114( ).hwp

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

Transcription:

: 31 2 2004 Kor. J. Fertil. Steril., Vol. 31, No. 2, 2004, 6 GnRH-agonist PBR 1, 2, 3 1 2 1 1 3 1 2 1 Apoptosis and Peripheral Benzodiazepin Receptor (PBR) Expression in Human Granulosa-Luteal Cells by GnRH-agonist Sei Kwang Kim 1, Yun-Hee Youm 2, Jeong-Mi Yoon 1, Sang Wook Bai 1, Hyunwon Yang 3, Dong Jae Cho 1, Yong-Dal Yoon 2, Chan Ho Song 1 1 Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, 2 Department of Life Sciences, College of Natural Sciences, Hanyang University Life Science Institute, 3 Eulji University School of Medicine Objective: To investigate whether GnRH-agonist (GnRH-Ag) using in IVF-ET affects apoptosis of human granulosa-luteal cells and expression of peripheral benzodiazepine receptor (PBR) protein involved in the apoptosis of the cells. Methods: Granulosa-luteal cells obtained during oocyte retrieval were cultured and treated with 10 5 M GnRH-Ag. Apoptosis of the cells by the treatment was confirmed using DNA fragmentation analysis 24 h after culture. The presence of PBR protein within the cells was examined by immunofluorescence staining and the expression of the protein was analyzed by Western blotting. In addition, it was measured for progesterone and nitric oxide (NO) produced by granulosa-luteal cells after GnRH-Ag treatment. To evaluate the relationship between NO production and PBR expression, sodium nitroprusside (SNP) as a NO donor was added in media and investigated the expression of PBR protein by Western blotting. Results: Apoptosis increased in the granulosa-luteal cells 24 h after GnRH-Ag treatment, whereas the expression of PBR protein significantly decreased. Furthermore, the production of progesterone and nitric oxide (NO) by the cells significantly fell from 12 h after the treatment. In the results of Western blotting after SNP treatment, the expression of PBR protein increased in the treatment with SNP alone to the granulosa-luteal cells, but was suppressed in the treatment with GnRH-Ag and SNP. Additionally, the staining result of PBR protein in the cells showed the even distribution of it through the cell. Conclusion: These results demonstrate that GnRH-Ag treatment induces apoptosis, decreasing expression of PBR protein and NO production in human granulosa-luteal cells. The present study suggests that one of the apoptosis mechanism of human granulosa-luteal cells by GnRH-Ag might be a :, ) 120-752 134, Tel: (02) 361-5499, Fax: (02) 313-8357, e-mail: skkim@yumc.yonsei.ac.kr * 2002. - 83 -

signal transduction pathway via NO and PBR. Key Words: Apoptosis, GnRH-agonist, Granulosa-luteal cells, Nitric Oxide (NO), Peripheral benzodiazepine receptor (PBR) (GnRH). 11 GnRH-Ag 10 peripheral benzodiazepine receptor (PBR) steroidogenic acute FSH LH,. 1 GnRH GnRH GnRH. 4. 15 NO nitric oxide synthase GnRH (NOS), 16, 17 18,, 19, 20., GnRH cyclic nucleotide 21 LH prolactin FSH, LH, IGF-1 estradiol progesterone progesterone, androgen estro-. 19,22 gen. 5 NO GnRH, 6 inhibin. 7 GnRH GnRH regulatory (StAR). 12 PBR StAR. 13 PBR. 2 GnRH, PBR GnRH GnRH. 3. 14 Nitric oxide (NO). NO. 23 NO, NO. 24 NO. 8,9 GnRH IGFBP-4 GnRH, (atresia) GnRH-Ag,. 10. GnRH Bax GnRH-Ag NO NO Bcl-xL, PBR - 84 -

GnRH. 70%. 1 ml 100,000. 24-well culture plate (Nunc, Denmark) 1 well ( 1 ml) (IVF-ET) 100,000, 37 95%. 5% CO 2 100% hmg (Meri-. Dulbecco's Modified onal; IBSA, Swiss) hfsh (Metrodin; Serono, Swiss) Eagle Medium (dmem; GIBCO BRL) 10% fetal bo-. vine serum (FBS; GIBCO BRL) 2 mm L-glutamine (step-down fashion) (GIBCO BRL), 100 U/ml penicillin (GIBCO BRL),, hmg hfsh 4 100 µg/ml streptomycin (GIBCO BRL) (Medison 128; Medison Co., Korea), hmg. 18 mm 17 mm 2 hcg (Profasi; Serono, Swiss) 10,000 IU. hcg 35 36.. NO PBR. St. Louis, MO) GnRH-Ag Hemonglobin (Sigma, St. Louis, MO). 24 PBR NO. 1 ml 40% percoll 3 ml 300 xg 20. 0.2 ml.. 3 0.1% collagenase (Sigma, St. Louis, MO). 37 30 26 G heamocytometer. trypan blue, chloroform: isoamyl alco- hol (24:1, V:V). 1.5 ml - 85 -. 24-well culture plate 24 plate. 10 6 M GnRH-Ag (Sigma, St. Louis, MO) NO SNP (Sigma, 12.5 µl 10% SDS 65 30. 35 µl 8 M potassium acetate 60 4, 5000 xg 10. 1.5 ml phenol: chloroform: iso- amyl alcohol (25:24:1, V:V:V) DNA

, 0 2.5 20, protease inhibitors (0.1 mm phenyl methyl-sulfonyl- 100% ethanol, -70 fluoride, 5 g/ml aprotinin, and 5 g/ml leupeptin) 1. 4 homogenization buffer 12,000 xg 14,000 xg 30 DNA 30. DC 50 µl 1X TE buffer (10 mm Tris-HCl, 1 protein assay kit (Bio-Rad Laboratories, Inc., Hercules, mm EDTA, ph 8.0) 1 µl DNasefree RNase (500 µg/ml; Boehringer-Mannheim, IN) 60 37. DNA phenol : chloroform : isoamyl alcohol, chloroform: isoamyl alcohol. 0.1 3 M sodium acetate 0 2.5 100% ethanol DNA -70 60. 4 14,000 xg 30, 0 0.2 ml 80% ethanol. 25 µl, 260 nm DNA -20. DNA lane 5 µg 1.5% agarose logy, Santa Cruz, CA) TTBS 1:1,000 gel loading, running buffer TBE 40., 50 V 3 membrane chemiluminescence (ECL kit; ethidium bromide tran- Amersham Life Science, Buckinghamshire, U.K.) silluminator. Science, Buckinghamshire, U.K.). NO nitrate/nitrite colorimetric assay kit (Alexis PBR Biochemicals, San Diego, CA), 1%. 10 kda molecular mass cut-off filter (Amicon, Millipore Co., Bedford, MA). goat nor-, nitrate reductase enzyme cofactor 3. sulfanila- rabbit polyclonal mide N-[1-naphthyl] ethylenediamine 1. PBS 10 microplate reader (Spectra Max 250, Molecular Devices, Sunnyvale, CA) anti-rabbit IgG (Jackson Immuno Research laboratories, 540 nm.. Propidium Iodide. 50 mm Tris-base PBR (Ni- (ph 7.4), 150 mm NaCl, 10 mm EDTA, 0.1% Tween- kon, Tokyo, Japan). - 86 - CA, U.S.A.) 10% SDS-PAGE. blotting nitro-cellulose membrane, 5% non-fat dry milk Tris-buffered saline (TTBS; 10 mm Tris (ph 7.6), 150 mm NaCl, 0.1% Tween-20) 1 blocking. Blocking membrane rabbit polyclonal anti-human PBR (Trevigen, Gai- thersbug, MD) 1:1,000 TTBS 1. TTBS 1 3 anti-rabbit horseradish peroxidase-conjugated antibody (Santa Cruz Biotechno- X-ray film (Hyperfilm, Amersham Life paraformaldehyde PBS mal serum 30. anti-human PBR, 1:100 fluorescein isothiocyanate (FITC) West Grove, PA) 30

one-way ANOVA stu- 4h 24 h Marker Saline GnRH Saline GnRH dent's t-test p 0.05. GnRH-Ag DNA. 4 GnRH-Ag DNA. 24 DNA GnRH-Ag (Figure 1). A 4 h 12 h 24 h Saline GnRH Saline GnRH Saline GnRH PBR Figure 1. Effects of GnRH-Ag treatment on DNA fragmentation in the cultured human granulosa-luteal cells. The cells cultured for 24 h showed an increase in DNA fragmentation in GnRH-Ag treatment compared with those in the saline. β-actin B Figure 2. Nitric oxide levels in the medium (mean EM; n = 5) at points timed after initiation of the treatment. *p<0.05 compared with corresponding saline controls. Figure 3. Western blot analysis (mean EM; n = 5) of PBR proteins in the granulosa-luteal cells at points timed after the commencement of treatment. *p<0.05 compared with corresponding saline controls. - 87 -

12 GnRH-Ag 3.33 0.66 µm/ml 6.21 1.52 µm/ml Figure 2 GnRH-Ag NO. NO (p<0.05), 24 2.35 0.91 µg/ml 4.04 1.23 µg/ml A SNP (mm) Saline 0.01 0.1 1 A Saline SNP SNP+ SNP Hb GnRH Hb +GnRH PBR PBR β-actin β-actin B B C C Figure 4. Western blot analysis (mean EM; n = 5) of PBR protein in the granulosa-luteal cells (A & B) and nitric oxide levels (mean EM; n = 5) in the medium 24 h after sodium nitroprusside (SNP) treatment in a dose-dependent manner. *p<0.05 compared with corresponding saline controls. Figure 5. Western blot analysis (mean EM; n = 5) of PBR protein in the granulosa-luteal cells (A & B) and nitric oxide levels (mean EM; n = 5) in the medium 24 h after treatment with GnRH-Ag, sodium nitroprusside (SNP), or hemoglobin (Hb). *p<0.05 compared with corresponding saline controls. - 88 -

(p<0.05). PBR SNP (239.11 23.12) Hb (178.56 13.32) PBR. GnRH-Ag, 4 (123.98 21.87) SNP PBR, 12 GnRH-Ag (71.34 10.21) (48.67 6.98) (p<0.05). 24 GnRH- Ag (72.78 12.32) (43.34 5.22) (p<0.05) (Figure 3). Hb (8.95 1.93 µg/ml). GnRH-Ag NO SNP PBR, PBR 0.01 mm SNP (62.48 Hb (2.10 1.09 µg/ml) GnRH-Ag (1.97 0.91 µg/ml) 9.20) 0.1 mm SNP (121.09 11.11) PBR 1 mm SNP (48.76 4.23) (5.66± 1.24 µg/ml) (Figure 4B). NO (Figure 5C). SNP (Figure 4C). Figure 5 0.1 mm SNP, Hb GnRH- Ag PBR PBR NO.. Hb (72.13 17.09) GnRH-Ag (81.98 19.09) PBR (113.60 13.54) (Figure 5B). NO SNP (23.21 2.12 µg/ml), NO SNP 19.78 2.67 µg/ml. A B Figure 6. Localization of PBR protein in the cultured human granulosa-luteal cells. Green spots displaying PBR expression localize on mitochondria in even throughout the cell. A; Fluorescent and B; Light microphotographs. Original magnification X400. - 89 -

, Bax Bcl-xL (Figure 6).. 11,14 GnRH GnRH-Ag. 28 GnRH, GnRH. GnRH-Ag NO. 25 FSH GnRH-Ag. 29, GnRH-Ag. 26 GnRH, GnRH-Ag. GnRH-Ag GnRH-Ag NO PBR. GnRH- GnRH-Ag. GnRH-Ag GnRH-Ag DNA. 24 DNA GnRH-Ag. GnRH-Ag DNA,,, GnRH-Ag. GnRH-Ag, 27 GnRH-Ag. NO PBR - 90 - GnRH-Ag NO. 30 NO,. 31 NO. GnRH-Ag NO Ag NO. GnRH-Ag NO NOS, GnRH-Ag NO NOS. 32 NO S-nitroso-N-acetyl-DL-penicillamine, 33 SNP FSH. 34 GnRH-Ag NO PBR

NO potential SNP PBR (proapoptotic). PBR, NO PBR. 1 MPT mm SNP NO, PBR potential. NO. NO PBR NO SNP NO Hb PBR. SNP 4864 PK 11195 PBR, Hb. 40 PBR. GnRH-Ag SNP PBR. SNP NO Hb. NO. GnRH-Ag - PBR 18 kda. 35 PBR Ro5-4864 isoquinoline carboxamide benzodiazepine voltagedependent anion channels 1. Barbieri RL, Hornstein MD. Assisted reproduction-in. 36 oxidative pho- vitro fertilization success is improved by ovarian sphorylation, stimulation with exogenous gonadotropins and pi- tuitary suppression with gonadotropin-releasing hor-. 13 mone analogues. Endocr Rev 1999; 20: 249-52. PBR 2. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig. 32 M, Felberbaum RE, Diedrich K, et al. Nonsupple- mented luteal phase characteristics after the admi-. 38 PBR nistration of recombinant human chorionic gonado- tropin, recombinant luteinizing hormone, or gona-. dotropin-releasing hormone (GnRH) agonist to in- (mitochondrial permeability transition pore; MPT) duce final oocyte maturation in in vitro fertilization - 91 -. PBR ligand., leukae- mic cells (HL 60) PBR ligand PK 11195, Ro5-4864, pyrrolo-1,5-benzoxazepines. 39 Ro5- NO. GnRH-Ag PBR. NO GnRH-Ag PBR PBR NO SNP. NO GnRH, NO PBR

patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003; 88: 4186-92. 3. Peng C, Fan NC, Ligier M, Vaananen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 1994; 135: 1740-6. 4. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995; 80: 430-4. 5. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure function relationships. Endocr Rev 1985; 6: 371-99. 6. Rippel RH, Johnson ES. Inhibition of hcg-induced ovarian and uterine weight augmentation in the immature rat by analogs of GnRH. Proc Soc Exp Biol Med 1976; 152: 432-6. 7. Bicsak TA, Tucker EM, Cappel S, Vaugham V, Rivier J, Vale W, et al. Hormonal regulation of granulosa cell inhibin biosyuthesis. Endocrinology 1986; 114: 2711-9. 8. Parborell F, Dain L, Tesone M. Gonadotropin-releasing hormone agonist affects rat ovarian follicle development by interfering with FSH and growth factors on the prevention of apoptosis. Mol Reprod Dev 2001; 60: 241-7. 9. Takekida S, Matsuo H, Maruo T. GnRH agonist action on granulosa cells at varying follicular stages. Mol Cell Endocrinol 2003; 202: 155-64. 10. Erickson GF, Li D, Sadrkhanloo R, Liu XJ, Shimasaki S, Ling N. Extrapituitary actions of gonadotropin-releasing hormone: stimulation of insulin-like growth factor-binding protein-4 and aterisa. Endocrinology 1994; 134: 1365-72. 11. Sridaran R, Hisheh S, Dharmarajan AM. Induction of apoptosis by a gonadotropin-releasing hormone agonist during early pregnancy in the rat. Apoptosis 1998; 3: 51-7. 12. Sridaran R, Lee MA, Haynes L, Srivastava RK, Ghose M, Sridaran G, et al. GnRH action on luteal steroidogenesis during pregnancy. Steroids 1999; 64: 618-23. 13. Papadopoulos V, Amri H, Boujrad N, Cascio C, Culty M, Garnier M, et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997; 62: 21-8. 14. Papadopoulos V, Dharmarajan AM, Li H, Culty M, Lemay M, Sridaran R. Mitochondrial peripheral-type benzodiazepine receptor expression: correlation with gonadotropin-releasing hormone (GnRH) agonistinduced apoptosis in the corpus luteum. Biochem Pharmacol 1999; 58: 1389-93. 15. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42. 16. Hesla JS, Preutthipan S, Maguire MP, Chang TS, Wallach EE, Dharmarajan AM. Nitric oxide modulates human chorionic gonadotropin-induced ovulation in the rabbit. Fertil Steril 1997; 67: 548-52. 17. Jablonka-Shariff A, Olson LM. The role of nitric oxide in oocyte meiotic maturation and ovulation: meiotic abnormalities of endothelial nitric oxide synthase knock-out mouse oocytes. Endocrinology 1998; 139: 2944-54. 18. Van Voorhis BJ, Dunn MS, Snyder GD, Weiner CP. Nitric oxide: an autocrine regulator of human granulosa-luteal cell steroidogenesis. Endocrinology 1994; 135: 1799-806. 19. Dixit VD, Parvizi N. Nitiric oxide and the control of reproduction. Anim Reprod Sci 2001; 65: 1-16. 20. Shukovski L, Tsafriri A. The involvement of nitric oxide in the ovulatory process in the rat. Endocrinology 1994; 135: 2287-90. 21. Jablonka A, Olson LM. The role of nitric oxide in oocyte meiotic maturation and ovulation: meiotic abnormalities of endothelial nitric oxide synthase knock-out mouse oocytes. Endocrinology 1998; 139: 2944-54. - 92 -

22. Olson LM, Jones-Burton CM, Jablonka-Shariff A. Nitric oxide decreases estradiol synthesis in rat luteal cells in vitro: possible role for nitric oxide in functional luteal regression. Endocrinology 1996; 137: 3531-39. 23. Smith CJ, Richards JS, Yasin K, Sangster JN, Sridaran R. Changes in rat luteal ultrastructure and P450scc mrna and protein content after in vivo treatment with a gonadotropin-releasing hormone agonist. Biol Reprod 1991; 44: 382-91. 24. Nelson SE, McLean MP, Jayatilak PG, Gibori G. Isolation, characterization, and culture of cell subpopulations forming the pregnant rat corpus luteum. Endocrinology 1992; 130: 954-66. 25. Pellicer A, Tarin JJ, Miro F, Sampaio M, De los Santos MJ, Remohi J. The use of gonadotrophin releasing-hormone analogues (GnRHa), in in-vitro fertilization: some clinical and experimental investigations of a direct effect on the human ovary. Hum Reprod 1992; 7 Suppl 1: 39-47.32. 26. Herman A, Ron-El R, Golan A, Raziel A, Soffer Y, Caspi E. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropinreleasing hormone analog and menotropins. Fertil Steril 1990; 53: 92-6. 27. Billig H, Furuta I, Hsueh AJW. Gonadotropin-releasing hormone (GnRH) directly induces apoptotic cell death in the rat ovary: biochemical and in situ detection of deoxyribonucleic acid fragmentation in granulosa cells. Endocrinology 1994; 134: 245-52. 28. Peng C, Fan NC, Ligier M, Vaananen J, Leung PCK Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa luteal cells. Endocrinology 1994; 135: 1740-6. 29. Chun SY, Eisenhauer KM, Kubo M, Hsueh AJW. Interleukin-1β suppresses apoptosis in rat ovarian follicles by increasing nitric oxide production. Endocrinology 1995; 136: 3120-7. 30. Kim YM, Bombeck CA, Billiar TR. Nitric oxide as a bifunctional regulator of apoptosis. Circ Res 1999; 84: 253-6. 31. Basini G, Baratta M, Ponderato N, Bussolati S, Tamanini C. Is nitric oxide an autocrine modulator of bovine granulosa cell function? Reprod Fertil Dev 1998; 10: 471-8. 32. Yang H, Bhat GK, Wadley R, Wright KL, Chung BM, Whittaker JA, et al. Gonadotropin-releasing hormone-agonist inhibits synthesis of nitric oxide and steroidogenesis by luteal cells in the pregnant rat. Biol Reprod 2003; 68: 2222-31. 33. Matsumi H, Koji T, Yano T, Yano N, Tsutsumi O, Momoeda M, et al. Evidence for an inverse relationship between apoptosis and inducible nitric oxide synthesis expression in rat granulosa cells: a possible role of nitric oxide in ovarian follicle atresia. Endocr J 1998; 45: 745-51. 34. Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJW. Hormonal regulation of apoptosis in early antral follicle: follicle-stimulating hormone as a major survival factor. Endocrinology 1996; 137: 1447-56. 35. Gavish M, Bachmann I, Shoukrun R, Katz Y, Veenman L, Weisinger G, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999; 51: 629-50. 36. McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine dinucleotide carrier. Proc Natl Acad Sci USA 1992; 89: 3170-4. 37. Bono F, Lamarche I, Prabonnaud V, Le Fur G, Herbert JM, Peripheral benzodiazepine receptor agonists exhibit potent anti-apoptotic activities. Biochem Biophys Res Commun 1999; 265: 457-61. 38. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998; 1366: 151-65. 39. Fennell DA, Corbo M, Pallaska A, Cotter FE. Bcl-2 resistant mitochondrial toxicity mediated by the isoquinoline carboxamide PK 11195 involves de - 93 -

novo generation of reactive oxygen species. Br J Cancer 2001; 84: 1397-404. 40. Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, et al. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22 a benzazepine. Proc Natl Acad Sci USA 2000; 97: 7494-9. - 94 -